Biotage has entered into an agreement to acquire Astrea Bioseparations, a high-growth chromatography solutions provider from Gamma Biosciences. The enterprise value for Astrea is approximately 190 million USD, subject to
Nordic Life Science
Pharma news from the Nordic life science industry
Latest news
Affibody and Chiesi Group have announced the execution of a collaboration and licensing agreement to develop and commercialize innovative treatments for respiratory diseases using Affibody’s technology. Under the terms of
Novo Nordisk has announced plans to expand its research and development (R&D) presence in the greater Boston metro area, creating one of its largest R&D hubs outside of Denmark. This
The US Patent and Trademark Office (USPTO) and the Japanese Patent Office have informed Diamyd Medical that they will grant the patent for the company’s oral formulation of the GABA-based
The European Health Data and Evidence Network (EHDEN) and Lundbeck have begun formative stages of neuroscience research with the EHDEN network and potential partners, including other pharma companies. Lundbeck joined the
The Ministry of Health, Labor and Welfare (MHLW) in Japan has approved the oral androgen receptor inhibitor (ARi) darolutamide plus ADT in combination with docetaxel in the indication of metastatic
Hemab Therapeutics has announced the closing of an oversubscribed Series B financing. The round was led by Access Biotechnology with participation from new investors Deep Track Capital, Avoro Ventures, Invus,
The European Commission has granted conditional marketing authorization (CMA) for CSL’s HEMGENIX, the first and only one-time gene therapy for the treatment of severe and moderately severe hemophilia B in
Aqilion has announced an exclusive license and strategic research collaboration with Merck to discover, develop and commercialize small molecule inhibitors of the transforming growth factor-β-activated kinase 1 (TAK1) protein. “We
Orexo has announced the submission of a New Drug Application to the US Food and Drug Administration for its lead pharmaceutical pipeline asset, OX124, a nasal rescue medication for opioid
Forxiga has been approved in the European Union to extend the indication for heart failure (HF) with reduced ejection fraction (HFrEF) to cover patients across the full spectrum of left
Clinical trials
Spago Nanomedical has received regulatory approval to initiate a Phase IIa clinical study with its MRI contrast agent SN132D in endometriosis. Patient recruitment has started, and the first patient is
The company has announced that the first patient was dosed in a trial evaluating bemcentinib in combination with the current standard of care, immune checkpoint inhibitor pembrolizumab and doublet chemotherapy,
Calliditas Therapeutics has announced results from the global, randomized, double-blind, placebo-controlled Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon versus placebo in patients with primary IgA nephropathy.
The company has announced the completion of the patient enrollment in the company’s phase 3 clinical study SPARKLE with the lead candidate drug Orviglance. “We are very pleased to have
The company has reported favorable safety and promising early signs of efficacy following an initial analysis of the phase Ib part of the clinical trial TRIFOUR. In collaboration with the
Modus Therapeutics has announced positive top-line data from its lipopolysaccharide (LPS) provocation study, a key step in evaluating the potential of its lead asset, sevuparin, as a treatment for sepsis
The company has announced topline data from BGBC008, a phase 2 trial evaluating its lead compound bemcentinibin combination with MSD’s anti-PD-1 therapy pembrolizumab in 2L+ Non-Small Cell Lung Cancer (NSCLC)
Guard Therapeutics have announced that 134 of the planned 268 patients have been dosed in the global randomized, double-blinded and placebo-controlled Phase 2 clinical trial (AKITA). The AKITA study has
Heartseed has successfully dosed the first patient in a phase 1/2 clinical study (LAPiS Study) with HS-001 – an investigational cell therapy for heart failure. An independent safety evaluation committee
Sustainability
At Orion Pharma’s Fermion plant waste ethanol is used to reduce the nitrogen load in the Baltic Sea. Outside Hanko in Finland, two different plants are located side-by-side. One of
The manifesto, launched by the trade association for the research-based pharmaceutical industry in Sweden (Lif), includes nine commitments that covers the entire value chain of medicines, from research and development
The professorship at the University of Helsinki, which is being established with the support of a fund, is aimed at strengthening sustainable development expertise in pharmacy across the globe. The
IVL Swedish Environmental Research Institute and Simrishamn Municipality have tested a completley new treatment system that has now been added to the Stengården sewage plant in Simrishamn, Sweden. “Removing pharmaceutical
Nordic efforts to prevent pharmaceuticals affecting the environment include Danish management of hospital wastewater and a Swedish large-scale sewage plant for removal of pharmaceutical residues. Wastewater from hospitals can contain